56.3 F
New York
Tuesday, May 17, 2022

Humanigen [NASDAQ: HGEN] Announces Expansion Of Manufacturing Agreement With Ajinomoto Bio-Pharma

Must read

Humanigen Inc [NASDAQ: HGEN] revealed that the company has extended the manufacturing agreement with  Ajinomoto BioPharma to support the fill-finish of Lenzilumab. The Lenzilumab is the phase 3 treatment option for Covid19 which is currently in development.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .


Ajinomoto will provide drug product aseptic fill-finish service to Humanigen at its San Diego facility. By doing so the company will simplify the supply chain efforts for Humanigen to support continuing clinical trials efforts. Meanwhile, Humangien is keenly registering patients in the United States and Brazil for a phase 3 study. Moreover, the company is preparing applications for Covid 19 EUA for Lenzilumab.

Cameron Durrant CEO of Humanigen said “ We are glad to join forces with Ajinomoto BioPharma to support the fil finish of Lenzilumab. Moreover, The collaboration will enable us to use Ajinomoto’s drug product aseptic fill-finish facility to provide the timely supply of Lenzilumab.  We are nearly at end of the clinical study of phase 3 and ready for Emergency Use Authorization applications.”

More articles

Latest article